Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Kringle Pharma, a Japan-based developer of therapeutics for intractable neurological diseases spun out of Osaka University, has increased its latest round to $15m after raising a ¥740m ($6.5m) extension led by the institution’s Osaka University Venture Capital, with participation from property group Chishima Real Estate and clinical test drugs supplier Miraca’s corporate venturing arm, as well as Yitu Capital, Resona Capital, an unnamed fund co-run by Nanto Bank and Venture Labo Investment, MSF Capital Partners, HT Capital, OKB Capital and assorted private investors. The spinout had raised an initial $8.5m in February 2020 from backers including existing shareholder Keio Innovation Initative and Tohoku University Venture Partners, respective investment arms of Keio University and Tohoku University, as well as Nippon Zenyaku Kogyo, a supplier of medical products for animals, pharmaceuticals distributor Toho Holdings, Cybernics Excellence Japan, medical web portal M3, consultancy POC Clinical Research, DBJ Capital – a subsidiary of Development…
